Price$270.28+1.32 (+0.49%)
01:30 PM07:45 PM
News · 26 weeks107+31%
2026-02-222026-08-16
Mix4890d
- Other28(58%)
- Insider7(15%)
- SEC Filings7(15%)
- Earnings3(6%)
- Leadership2(4%)
- Dividends1(2%)
Latest news
25 items- INSIDEREVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDERCEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRJohnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260810189263/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.
- INSIDERCEO and Chairman of the Board Duato Joaquin sold $12,515,010 worth of shares (48,480 units at $258.15), decreasing direct ownership by 15% to 275,967 units (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- INSIDEREVP, Chief Legal Officer Forminard Elizabeth exercised 9,344 shares at a strike of $131.94 and sold $4,090,960 worth of shares (15,918 units at $257.00), decreasing direct ownership by 28% to 16,994 units (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- SECSEC Form 13F-HR filed by Johnson & Johnson13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
- PRA CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 ReadoutNEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - In biotech, the gap between a promising drug and a commercial success is often bridged by a single thing: the operator who has done it before. Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP), a clinical-stage company developing novel treatments for depression and anxiety, has just brought in exactly that kind of operator, appointing Michael Halstead, the former President of Intra-Cellular Therapies, as Chief Executive Officer, effective immediately. The move lands months before the company's first pivotal Phase 3 data readout, and it places Helus alongside a cohort of companies working to modernize psychiatric treatmen
- PRJohnson & Johnson to Participate in the 2026 Wells Fargo Healthcare ConferenceJohnson & Johnson (NYSE:JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9th, 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260804385778/en/ Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com
- PREvery Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) to InMode (NASDAQ:INMD) and Anika Therapeutics (NASDAQ:ANIK), built enormous businesses around them. Now a wave of new demand is exposing the limits of the existing categories, and a preclinical company, Con
- SECJohnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPriority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET, proven drivers of tumor growth and treatment resistance RARITAN, N.J., July 30, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics Lice
- PRJohnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology InnovationBroadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation Johnson & Johnson (NYSE:JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent a
- PRJohnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune ResetAdvances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership in immunology and CAR-T innovation Grants Johnson & Johnson an exclusive option to acquire Sail Johnson & Johnson1 (NYSE:JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with
- SECJohnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRCovista Names Emily C. Chiu and Leslie Storms to its Board of DirectorsAppointments Deepen the Board’s Expertise Across Healthcare Delivery, Technology, Higher Education and Veterinary Medicine Supports Effective Oversight of the Company’s Growth and Long-Term Strategy Covista (NYSE:CVSA), America's largest healthcare educator, today announced the appointments of Emily C. Chiu and Leslie Storms to its Board of Directors, effective August 17, 2026. Ms. Chiu and Ms. Storms join the Covista Board at an important moment as Covista embarks on Purpose at Scale, its three-year growth strategy to address the nation's healthcare workforce challenges. Ms. Chiu is a former CEO with deep experience in technology, fintech and edtech, and brings a builder's perspecti
- SECJohnson & Johnson filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - JOHNSON & JOHNSON (0000200406) (Filer)
- PRJohnson & Johnson Announces a Proposed Resolution of Ovarian Talc LitigationFollows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining Roughly 76,000 Ovarian Talc Claims Johnson & Johnson (NYSE:JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by t
- SECSEC Form 10-Q filed by Johnson & Johnson10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
- PRTECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomaInvestigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myelomaFifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journeyRARITAN, N.J., July 23, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI® (teclistamab-cqyv) + TALVEY® (tal
- PRJohnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical SystemBuilt to open new possibilities in surgery, OTTAVA™ creates a new category in soft tissue robotics System authorized for use in multiple procedures in general surgery within the upper abdomen System features are designed to enable surgical teams and hospitals to expand OR capacity, streamline clinical workflows, and elevate surgical performance Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world’s first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, g
- INSIDEREVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)4 - JOHNSON & JOHNSON (0000200406) (Issuer)
- PRA Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps WideningIssued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and the numbers behind it are staggering. Tens of millions of adults live with major depressive disorder, and the majority never reach full remission on the first medication they try. That persistent treatment gap has drawn a wave of biotech and pharmaceutical companies into what is now one of the most closely watched races in interventional psychiatry, each pursuing a different way to reach patients that current antidepressants leave behind.
- PRBillions Flow Into Next-Generation Depression Treatments as Pharma Innovation AcceleratesMajor Depressive Disorder Market Poised for Strong Growth as New Drug Innovations Transform Patient CareNEW YORK, July 21, 2026 /CNW/ -- Market News UpdatesNews Commentary - Globally, Major Depressive Disorder (MDD) is a prevalent mental health condition that has seen an improvement in patient outcomes due to new approaches introduced by pharmaceutical companies. Traditionally, treatments focused on boosting serotonin levels or other neurotransmitters, resulting in long waiting periods for patients to notice any changes, without any assurance of effectiveness. However, there is now a shift towards quicker-acting medications, exploration of new biological targets, and the development of perso
- PRJohnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year AwardNew branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems. Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026. Johnson & Johnson (NYSE:JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change t
- PRDePuy Synthes Acquires Expanding Innovations™Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced it has acquired Expanding Innovations, Inc., an emerging leader in expandable implant technology for spine surgery. The transaction strengthens DePuy Synthes’ Spine portfolio and expands its position in the rapidly growing expandable interbody cage segment. Expanding Innovations (EI) is a commercial-stage medical technology company focused on developing and commercializing expandable implant technologies for spine surgery. Their proprietary, non-screw-b
JNJ FAQ
7 questionsWhat does Johnson & Johnson do?
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL...Where does JNJ stock trade?
Johnson & Johnson (JNJ) is listed on NYSE.What sector and industry is JNJ in?
Johnson & Johnson operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does JNJ pay a dividend?
Yes. JNJ's next ex-dividend date is 2026-08-25 with a declared cash dividend of $1.34 per share, payable 2026-09-08.What are analysts saying about JNJ?
Johnson & Johnson has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-05-13.What companies are similar to JNJ?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), PFE (Pfizer Inc.), UL (Unilever PLC). Compare JNJ side-by-side with any of them on Quantisnow.How can I track JNJ on Quantisnow?
Quantisnow aggregates Johnson & Johnson's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JNJ to receive live email and push alerts on every new disclosure.